Company Focus
Sanofi
Latest Sanofi News
Pharmaceutical
The European Medicines Agency (EMA) human medicines committee (CHMP) recommended five new medicines for approval at its April 2026 meeting. 24 April 2026
Related News
Insights
Company Spotlight
A Tokyo-headquartered biotechnology company leveraging its GPCR structure-based drug discovery platform to build a diversified pipeline spanning neuropsychiatric disorders, rare diseases, and autoimmune conditions across global markets.
Latest News & Features of interest to Sanofi
Pharmaceutical
US drug developer Cytokinetics today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock. 11 May 2026
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated safety advice to strengthen warnings about potential psychiatric and sexual dysfunction linked to finasteride and to provide precautionary advice on a similar product, dutasteride. 11 May 2026
Biotechnology
Daiichi Sankyo today revealed its next Five-Year Business Plan (FY2026 - FY2030) that outlines how the company plans to deliver more than 2.3 trillion yen ($14.64 billion) in oncology revenue by 2030 and be a global top five oncology company by 2035. 11 May 2026
Biotechnology
San Diego-based Capricor Therapeutics, a biotech developing cell and exosome-based therapeutics for rare diseases, has filed a lawsuit Japanese pharma against Nippon Shinyaku and its US subsidiary, NS Pharma. 11 May 2026
Pharmaceutical
This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s Phase III CARDIO-TTRansform trial was presented. 11 May 2026
Biotechnology
CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock closing down 16% at A$100.75, having fallen as much as 20%. 11 May 2026
Pharmaceutical
Japanese drugmaker Nxera Pharma has entered into a license agreement with a newly established company (NewCo) to advance a specific GPCR-targeted program owned by Nxera. Nxera shares rose 6.4% to 1,242 yen on the news. 11 May 2026
Biotechnology
Daiichi Sankyo has cut its operating profit forecast for fiscal 2025 after a reset of manufacturing plans for its antibody-drug conjugate business triggered 95 billion yen ($606 million) in expected charges. 11 May 2026
Pharmaceutical
Among important regulatory news last week, the US Food and Drug Administration (FDA) approved Axsome Therapeutics’ Alzheimer’s agitation candidate Auvelity, and an FDA Advisory Committee voted against approval of AstraZeneca’s breast cancer drug camizestrant. US biotech Madrigal Pharma revealed a deal with Arrowhead Pharma to acquire rights to its investigational MASH treatment ARO-PNPLA3. Germany’s Bayer announced its proposed acquisition of Perfuse Therapeutic, aiming to reinforce it ophthalmics drug pipeline. 10 May 2026
Biotechnology
The US Food and Drug Administration (FDA) late Friday approved a label expansion for Netherlands-based argenx’ Vyvgart efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG). 9 May 2026
Latest In Brief for Sanofi
Biotechnology
US Biotech company Regenxbio and the University of Pennsylvania on Friday convinced a US appeals court to revive their patent lawsuit against Sarepta Therapeutics over Sarepta's Duchenne muscular dystrophy (DMD) treatment, according to a Reuters report. 23 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze